Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Non Operating Income (2016 - 2025)

Capricor Therapeutics has reported Non Operating Income over the past 15 years, most recently at -$1.0 million for Q4 2025.

  • Quarterly results put Non Operating Income at -$1.0 million for Q4 2025, down 274.34% from a year ago — trailing twelve months through Dec 2025 was $3.1 million (up 47.77% YoY), and the annual figure for FY2025 was $3.1 million, up 47.77%.
  • Non Operating Income for Q4 2025 was -$1.0 million at Capricor Therapeutics, down from $1.7 million in the prior quarter.
  • Over the last five years, Non Operating Income for CAPR hit a ceiling of $1.8 million in Q2 2025 and a floor of -$1.0 million in Q4 2025.
  • Median Non Operating Income over the past 5 years was $399590.0 (2021), compared with a mean of $429076.5.
  • Biggest five-year swings in Non Operating Income: skyrocketed 9582.22% in 2021 and later crashed 274.34% in 2025.
  • Capricor Therapeutics' Non Operating Income stood at $189118.0 in 2021, then soared by 82.65% to $345433.0 in 2022, then surged by 50.3% to $519203.0 in 2023, then grew by 11.95% to $581238.0 in 2024, then crashed by 274.34% to -$1.0 million in 2025.
  • The last three reported values for Non Operating Income were -$1.0 million (Q4 2025), $1.7 million (Q3 2025), and $1.8 million (Q2 2025) per Business Quant data.